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finalized with input from principal investigators. Results: More than 2900 publica-
tions and 300 websites were screened, and 16 registries, 17 cohort studies and 43 data-
bases were reviewed. Nine data sources from seven countries were recommended, 
of which six complementary sources were included: Get With The Guidelines-Stroke 
in the USA (an in-hospital database including about 1600 hospitals); National Stroke 
Registry in China (132 hospitals); Fukuoka Stroke Registry in Japan (seven stroke 
centres); Clinical Research Centre for Stroke – 5thDivision Registry in South Korea 
(12 stroke centres); Riks-Stroke in Sweden (all Swedish hospitals admitting patients 
with acute stroke); and Erlangen Stroke Registry in Germany (Erlanger community). 
Based on a globally agreed study design concept, protocols for each data source have 
been developed locally and are now being implemented. ConClusions: The ARES 
programme will provide global, observational data from contemporary populations 
with mild stroke/TIA in real-world clinical practice. Studies will be presented individu-
ally owing to differences in the nature of the data sources.
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objeCtives: Health Technology Assessment of innovative biomedical devices still 
requires the effort to introduce dedicated Information Technology tools able to 
support the implementation of the evaluation process. The aim of the study was 
to systematize the collection, the management and the analysis of large volumes 
of multidimensional data in order to optimally conduct an HTA study of emerg-
ing technologies. Methods: We designed a relational database, subsequently we 
developed and implemented a centralized, web-based user-friendly data entry for 
Case Report Form (CRF) data collection. (i) The development of User Interface (UI), 
(ii) data anonymization, (iii) differentiate accesses, (iv) automated quality control 
checks for data entry, (v) appropriate system tables to make data entry uniform, and 
(vi) the possibility of creating final reports were addressed. In the data extraction 
phase, we used MySQL computer languages and combined PHP and HTML codes. 
Knowledge Discovery in Data process was implemented with different software 
and programming languages for automation of the data collection, extraction and 
analysis. Results: The IT tools have been applied to the first multicenter prospec-
tive Italian study of HTA on the da Vinci surgical system, obtaining meaningful end 
points in terms of costs and clinical outcomes. The study involved the enrolment of 
699 patients from the 8 Italian Teaching Hospitals in the period 2011-2014. Patients 
were enrolled and prospectively evaluated from the preoperative work-up till six 
months after the discharge. ConClusions: The IT tools developed allow research-
ers to more efficiently and effectively manage large volumes of various source of 
HTA data, enhancing data quality from storage to processing. The database design 
could be empowered and readjusted for other HTA studies in near future and the 
entire approach generalized. In the immature field of HTA of innovative biomedical 
devices, this example of application could promote the automation of the imple-
mentation process of HTA.
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objeCtives: The primary objective is to describe how patients with advanced STS 
are managed in France. The secondary objectives are to describe the epidemiologi-
cal characteristics, the diagnostic procedures as well as the therapeutic strategy for 
the management of patients with STS. Methods: This observational, retrospective 
and national study will use the patient databases of the European CONTICANET 
“CONnective TIssue Cancer NETwork” network and of the French networks: RRePS 
and NetSarc(Pathological and Clinical Reference Networks for Soft Tissues and 
Visceral Sarcomas) . All the data collected in these networks and compiled in the 
“Sarcoma clinicobiological database” will allow good national representativity of 
STS. The study period was defined to reflect the current situation in terms of diagno-
sis and disease management in France. Results: The European database currently 
contains data from 12,485 patients (pts) registered by the French Sarcoma Group 
centers with 9,736 soft tissues and visceral sarcomas. Data from STS patients, who 
were diagnosed between 2012 and 2013, will be extracted from the Conticabase 
database. Part of these data will be “chained” with the shared database from the 
French networks RRePS (24,000 pts) and NetSarc (28,000 pts). Results are expected at 
the end of 2015. ConClusions: This pharmacoepidemiological study shows how 
useful high-quality medical databases are to study rare diseases and their manage-
ment in real life. This study is carried out as part of a public/private partnership.
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objeCtives: Due to high prevalence of socially significant chronic diseases among 
children the introduction of information technologies in the process of interac-
tion between doctor and patient is important. The aim: to analyze the prospects 
of the development of remote monitoring systems, to identify their shortcomings 
and to propose solutions. Methods: The review had included 36 publications, 1 
meta-analysis concerning telemedicine from 2001 to 2014 y. In the evaluated studies 
the following questions were explored: • research of social and economic aspects of 
The updated version of Charlson Comorbidity Index (CCI), for predicting resource 
utilisation, was never considered in such studies.
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objeCtives: The randomized clinical trials (RCT), as gold standard for evidence-
based medicine, have a number of shortcomings, and their results do not fully 
reflect actual clinical practice. In cases where RCTs are difficult to conduct because 
of ethical or other aspects, data bases of clinical cases - medical registries are used 
to determine the effectiveness and safety of any medical intervention in long-
term observation. Due to heterogeneity of clinical symptoms in different groups 
of patients with bronchial asthma (BA), to assess the efficacy and safety of treat-
ment of severe persistent uncontrolled asthma in the real clinical practice, the best 
practice is to use a long-term clinical monitoring. Aim - to create patient registry 
for children and adolescents with severe persistent uncontrolled BA. Methods: 
By experts of center in the result of system work software was created. It was shell 
for management of database of clinical cases – patient registry of children with 
uncontrolled severe persistent BA, who received Omalizumab as addition to basis 
therapy. Results: The database included information about 64 children (62.5% 
boys) from 6 to 17 y 11 mo (mean age 12.9 y) with severe persistent uncontrolled 
BA, who received / receive (31 patients, 70.9% boys) bioengineered treatment (dura-
tion of treatment from 1 till 70 mo). During the analyzed period of treatment safety 
of Omalizumab was confirmed: more than 5384 injections were conducted. Local 
adverse events were registered at frequency of 1/100 and were manifested as light 
redness, induration and light edema, were realized in 1-1.5 days after Omalizumab 
administration. Local allergic reactions such as rash were observed in two patients 
and were stopped by antihistamines ConClusions: The patient registry will help 
in solving problems as epidemiological, and in order to achieve optimal endpoints 
for monitoring and analysis of efficacy and safety of innovative high-tech medica-
tions and approaches which have been used previously for long time.
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objeCtives: Since 2012, the Italian Medicines Agency (AIFA-Agenzia Italiana del 
Farmaco), with the cooperation of CliCon, has been providing and updating the 
OsMed Health-DB Database, a nationwide standardized monitoring system to pro-
vide analyses, reports, and trends on appropriateness of medicines’ use and medica-
tion persistence, to inform decision-makers in order to improve health outcomes 
and to avoid wasting of health-care resources Methods: The OsMed Health-DB 
Database has two main components with distinct but complementary functions: a 
data-warehouse, a repository containing the integrated demographic, pharmaceuti-
cal and hospital discharges administrative data kept by Local Health Units (LHUs) 
and Regional Health Units (RHUs) and a dashboard, a set of performance indicators, 
with updates scheduled every six months, evaluating the prescription adherence 
to preset standards of some chronic pathologies at the local, regional, and national 
level. In 2014, 36 LHUs and 5 RHUs provided data, covering all Italian Regions and 
the data-warehouse stored information of about 30 million patients (almost the 
50.0% of the entire Italian population). Results: The 2014 OsMed Report reported 
the trend of 34 indicators on appropriateness and adherence of 10 chronic diseases: 
hypertension, hypercholesterolemia, diabetes mellitus, COPD, osteoporosis, depres-
sion, ulcers and esophagitis, anemia, psoriasis and rheumatoid arthritis. The average 
age of the LHU sample resulted 44.0 years versus 43.7 years of the Italian popula-
tion. The percentage of males resulted 48.5%, in accordance with the national data 
available. Medication persistence rate for all studied diseases averaged 43.3%, with a 
range of 13.9% of respiratory system drugs and 62.2% of anti-diabetic drugs. Results 
will be reported on “National Report on medicines use in Italy” available at AIFA 
website. ConClusions: Findings from the OsMed Health-DB Database highlighted 
that the majority of indicators is changing toward appropriateness and adherence. 
These findings prove that continuous monitoring of appropriateness and adherence 
is a driver for improving real-world use of medicines.
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objeCtives: Patients with mild stroke or transient ischaemic attack (TIA) are at 
high risk of recurrent stroke and other cardiovascular events. The Assessment of 
Real-world Evidence in Stroke/TIA (ARES) programme aims to characterize the 
management and outcomes of patients with mild stroke/TIA in real-world clinical 
practice using the most suitable data sources. Methods: In an initial Systematic 
Understanding of Real-world Evidence (SURE) assessment, suitable data sources 
(cohorts, registries and databases) were identified and characterized by systematic 
literature and web searches supplemented with e-mail and telephone contact. Data 
sources were recommended if they were active, representative, accessible, recorded 
National Institutes of Health Stroke Scale (NIHSS) scores or ABCD2 scores, and 
reported health resource utilization, ischaemic events and death during follow-up of 
at least 90 days (either direct or via linkage). The programme of included studies was 
